X-linked hypophosphatemia and growth

X-Linked hypophosphatemia (XLH) is the most common form of hereditary rickets caused by loss-of function mutations in the PHEX gene. XLH is characterized by hypophosphatemia secondary to renal phosphate wasting, inappropriately low concentrations of 1,25 dihydroxyvitamin D and high circulating level...

Full description

Saved in:
Bibliographic Details
Published in:Reviews in endocrine & metabolic disorders 2017-03, Vol.18 (1), p.107-115
Main Authors: Fuente, R., Gil-Peña, H., Claramunt-Taberner, D., Hernández, O., Fernández-Iglesias, A., Alonso-Durán, L., Rodríguez-Rubio, E., Santos, F.
Format: Article
Language:English
Subjects:
Animals
Diabetes
Endocrinology
Familial Hypophosphatemic Rickets - complications
Familial Hypophosphatemic Rickets - metabolism
Fibroblast Growth Factors - metabolism
Growth Disorders - drug therapy
Growth Disorders - etiology
Growth Disorders - metabolism
Humans
Internal Medicine
Medicine
Medicine & Public Health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:X-Linked hypophosphatemia (XLH) is the most common form of hereditary rickets caused by loss-of function mutations in the PHEX gene. XLH is characterized by hypophosphatemia secondary to renal phosphate wasting, inappropriately low concentrations of 1,25 dihydroxyvitamin D and high circulating levels of fibroblast growth factor 23 (FGF23). Short stature and rachitic osseous lesions are characteristic phenotypic findings of XLH although the severity of these manifestations is highly variable among patients. The degree of growth impairment is not dependent on the magnitude of hypophosphatemia or the extent of legs´ bowing and height is not normalized by chronic administration of phosphate supplements and 1α hydroxyvitamin D derivatives. Treatment with growth hormone accelerates longitudinal growth rate but there is still controversy regarding the potential risk of increasing bone deformities and body disproportion. Treatments aimed at blocking FGF23 action are promising, but information is lacking on the consequences of counteracting FGF23 during the growing period. This review summarizes current knowledge on phosphorus metabolism in XLH, presents updated information on XLH and growth, including the effects of FGF23 on epiphyseal growth plate of the Hyp mouse, an animal model of the disease, and discusses growth hormone and novel FGF23 related therapies.
ISSN:1389-9155
1573-2606
DOI:10.1007/s11154-017-9408-1